Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002742 · ClinicalTrials.gov registry record · Phase 3
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Phase 3 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 3
- Development phase
- 236
- Enrollment target
NCT01002742: Completed Phase 3 study, sponsored by Medical College of Wisconsin.
NCT01002742 is a Phase 3 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 236 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01002742, a Phase 3 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 236 participants
- Enrollment target
Study Summary
The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post randomization.
Primary Outcome
Success is defined as alive and free of GVHD at day 56 after randomization, all others are considered to be a study failure.
Interventions
- DRUG Placebo
- DRUG Mycophenolate Mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT01002742 record still lists
NCT01002742 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01002742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01002742 about?
NCT01002742 is a clinical study titled "Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)". The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post ra...
What is the current status of trial NCT01002742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2010-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01002742?
The interventions under investigation include: Placebo (DRUG), Mycophenolate Mofetil (DRUG).
Who is sponsoring clinical trial NCT01002742?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01002742's enrollment target sits among peer trials
236 1294th of 2000 higher than 705 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia